TGTX revenue +70% to $240.3M; operating income -38% as R&D doubles, debt refinancing adds loss

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 8, 2025 · ~2 min read

Key Changes

• high

  Revenue grew 70.3% YoY to $240.3M driven by BRIUMVI U.S. penetration and $14.6M ex-U.S. sales through Neuraxpharm. Operating income fell 38% to $21.7M as R&D spending nearly doubled ($131M vs $71M) for subcutaneous manufacturing scale-up and expanded clinical trials.

  MD&A: Revenue & Operating Results verify on EDGAR →
• high

  Debt refinanced in March 2026: $750M term loan replaced $250M facility, extending maturity to 2031 and lowering starting margin from 5.50% to 4.75%. Company recorded $9.2M loss on extinguishment (prepayment fees, unamortized costs write-off).

  Notes: Debt Refinancing view on EDGAR →
• high

  New stock tracking units (STUs) introduced as liability-classified equity awards, remeasured quarterly at stock price. STU expense was $15.3M in Q2 2026 (including $8.6M from stock-price remeasurement); $84.8M unrecognized expense remains over 3.6 years.

  Notes: Stock Tracking Units verify on EDGAR →